The Paediatric Allergy Research Group, Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, United Kingdom.
The Population Health Research Institute, St George's, University of London, London, United Kingdom.
JAMA Pediatr. 2020 Nov 1;174(11):1041-1047. doi: 10.1001/jamapediatrics.2020.2893.
There are no strategies for the prevention of celiac disease (CD). Current guidelines stating that the age at gluten introduction does not affect the prevalence of CD are based on the results from several randomized clinical trials, but the doses of gluten and timing of its introduction varied.
To determine whether early introduction of high-dose gluten lowers the prevalence of CD at age 3 years.
DESIGN, SETTING, AND PARTICIPANTS: The Enquiring About Tolerance (EAT) Study was an open-label randomized clinical trial. A total of 1303 children from the general population in England and Wales were recruited and followed up from November 2, 2009, to July 30, 2012. For the present study, samples were collected from November 1, 2012, to March 31, 2015, and data were analyzed from April 25, 2017, to September 17, 2018.
Infants were randomized to consume 6 allergenic foods (peanut, sesame, hen's egg, cow's milk, cod fish, and wheat) in addition to breast milk from age 4 months (early introduction group [EIG]) or to avoid allergenic foods and follow UK infant feeding recommendations of exclusive breastfeeding until approximately age 6 months (standard introduction group [SIG]).
Evaluation of CD was an a priori secondary end point of the EAT Study, and at age 3 years, all children with available serum samples were tested for antitransglutaminase type 2 antibodies. Children with antibody levels greater than 20 IU/L were referred to independent gastroenterologists for further investigation.
Of the 1004 infants included in the analysis, 514 were male (51.2%). The mean (SD) quantity of gluten consumed between ages 4 and 6 months was 0.49 (1.40) g/wk in the SIG and 2.66 (1.85) g/wk in the EIG (P < .001). Mean (SD) weekly gluten consumption ranged from 0.08 (1.00) g/wk at age 4 months to 0.9 (2.05) g/wk at age 6 months in the SIG vs 1.3 (1.54) g/wk at age 4 months to 4.03 (2.40) g/wk at age 6 months in the EIG. Seven of 516 children from the SIG (1.4%) had a diagnosis of CD confirmed vs none of the 488 children in the EIG (P = .02, risk difference between the groups using the bootstrap, 1.4%; 95% CI, 0.6%-2.6%).
In this analysis of infants in the EAT Study, the introduction of gluten from age 4 months was associated with reduced CD prevalence. These results suggest that early high-dose consumption of gluten should be considered as a strategy to prevent CD in future studies.
isrctn.org Identifier: ISRCTN14254740.
目前尚无针对乳糜泻 (CD) 的预防策略。目前的指南指出,引入麸质的年龄不会影响 CD 的患病率,这是基于几项随机临床试验的结果,但这些试验的麸质剂量和引入时间有所不同。
确定早期引入高剂量麸质是否会降低 3 岁时 CD 的患病率。
设计、设置和参与者:Enquiring About Tolerance (EAT) 研究是一项开放标签的随机临床试验。英国和威尔士的一般人群中共有 1303 名儿童被招募并进行了随访,从 2009 年 11 月 2 日至 2012 年 7 月 30 日。在本研究中,样本于 2012 年 11 月 1 日采集,并于 2015 年 3 月 31 日结束,数据分析于 2017 年 4 月 25 日至 2018 年 9 月 17 日进行。
婴儿从 4 个月大开始随机食用 6 种过敏原食物(花生、芝麻、鸡蛋、牛奶、鳕鱼和小麦),此外还食用母乳(早期引入组 [EIG]),或避免食用过敏原食物并遵循英国婴儿喂养建议,直到大约 6 个月大时才进行母乳喂养(标准引入组 [SIG])。
CD 的评估是 EAT 研究的一个预先设定的次要终点,在 3 岁时,所有有可用血清样本的儿童都接受了抗转谷氨酰胺酶 2 抗体检测。抗体水平大于 20 IU/L 的儿童被转介给独立的胃肠病学家进行进一步检查。
在纳入分析的 1004 名婴儿中,514 名为男性(51.2%)。SIG 组 4 至 6 个月间平均(SD)摄入的麸质量为 0.49(1.40)g/周,EIG 组为 2.66(1.85)g/周(P<0.001)。SIG 组从 4 个月大到 6 个月大,每周摄入的麸质量从 0.08(1.00)g 到 0.9(2.05)g 不等,而 EIG 组则从 4 个月大到 6 个月大,每周摄入的麸质量从 1.3(1.54)g 到 4.03(2.40)g 不等。SIG 组的 516 名儿童中有 7 名(1.4%)确诊为 CD,而 EIG 组的 488 名儿童中没有确诊(P=0.02,使用引导法计算的两组间风险差异为 1.4%;95%CI,0.6%-2.6%)。
在这项对 EAT 研究中的婴儿的分析中,4 个月大时引入麸质与 CD 患病率降低有关。这些结果表明,在未来的研究中,应考虑早期高剂量摄入麸质作为预防 CD 的策略。
国际临床试验注册平台标识符:ISRCTN82641002。